| Objective: To discuss the effect of single-nucleotide polymorphism(SNP)in methylenetetrahydrofolate reductase(MTHFR) on the Plasma Homocysteine(Hcy) levels, to investigate the relationship between the level of Hcy in patients with Parkinson’s disease(PD) and polymorphism in MTHFR, which will provide a theoretical foundation for the choice of medicine therapy in PD.Method: Collect clinical data from 68 PD patients(case group) and 64 healthy people(control group). People’s age and gender from control group are matched with those from case group. Test the level of Hcy, folic acid and vitamin B12 level in both groups. Test gene polymorphism through the method of restriction fragment length polymorphism-polymerase chain reaction amplification(RFLP-PCR). Acquire the results of MTHFR C677 T and A1298 C genotype and allelic genes regularities of distribution of patients from both groups through the experiment which is to do stratification analysis based on Hcy levels in case group.Then group t test,single factor analysis of variance and x2 test were used for statistical analysis by SPSS 22.0software. Typical samples are further investigated through genetic sequencing to verify the results. Analyze the risk factor of Parkinson’s disease and hyperhomocysteinemia by interaction analysis method.Results: Compared to control group, the serum Hcy levels of PD patients arestatistically significantly higher. There is no significant difference in Folic acid and vitamin B12 between two groups. Within the case group, a statistically negative correlation are found between the serum Hcy levels and folic acid as well as vitamin B12. The frequency distributions of C677 T allelic gene are significantly different between two groups(c2=4.882,P=0.027). T gene mutation frequency in case group is much higher than it in the control group. However, the phenomenon observed above is not found in MTHFR A1298 C. Within the case group, the level of folic acid in PD patients who are CT genotype is much higher than TT genotype carriers. TT genotype carriers’ Homocysteine levels in plasma are much higher than CT and CC genotype carriers’. There is no interaction between C677 T and A1298 C, which means the increase of gene mutation sites will not necessarily get a higher risk of Parkinson’s disease and Hhcy. Through this analysis within the case group, the result shows that C677 T and A1298 C gene mutation will not increase the risk of getting Hyperhomocysteinemia(Hhcy). Along with the increasing of T gene mutation at C677 T PD patients will have a higher risk of getting Hhcy.Conclusion: Through this research, a correlation between MTHFR C677 T and Hhcy was found. T gene mutation is likely to be an independent risk factor of PD patients with Hhcy. Correlation between MTHFR A1298 C and plasma Hcy level was not observed. Both MTHFR A1298 C and C677 T mutation acting together will not necessarily increase more chance of getting PD or Hhcy than MTHFR A1298 C or C677 T mutation alone. |
